Yash Suri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yash Suri has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Arnab Basu
University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, Birmingham, AL, USA
1 shared publication Bassel El‐Rayes
Emory University School of Medicine, and Winship Cancer Institute Georgia
1 shared publication- Chinedum O. Ojinnaka
College of Health Solutions, Arizona State University, Phoenix, Arizona, USA
1 shared publication Christina Boulton
Department of Orthopedic Surgery, Banner – University Medical Center, Tucson, AZ, United States of America
1 shared publication- Constance van Eeghen
University of Vermont Division of Public Health, Department of Medicine, 89 Beaumont Avenue, Burlington, VT, 05405, United States
1 shared publication - Daniel Mullin
Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, USA
1 shared publication
Latest Publications
- Open Access
- 25 July 2024
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 9 (4) , 197-205
Musculoskeletal manifestations of lower-extremity coccidioidomycosis: a case series
Background: Coccidioidomycosis is a fungal infection endemic to the southwestern United States. Musculoskeletal manifestations are uncommon and seen in disseminated disease. While the involvement of the axial skeleton has been well described, the literature is limited on diseases involving the lower extremity. Methods: We identified three patients, at two regional academic medical centers in southern Arizona, who demonstrated different manifestations of osteoarticular coccidioidomycosis involving the lower extremity. Results: Case 1 is a 41-year-old male, with a history of HIV/AIDS and vertebral coccidioidomycosis, who presented with abscesses in the left hemipelvis and left proximal femoral osteomyelitis. He was treated with staged surgical debridement, including the use of amphotericin B impregnated beads. He remains on indefinite oral posaconazole suppression. Case 2 is a 46-year-old female, who presented with suspected right knee osteoarthritis. An MRI revealed septic arthritis and osteomyelitis. Necrotic bone was debrided, and synovial fluid cultures were positive for Coccidioides. She underwent a resection of the native knee joint with the insertion of an amphotericin B and voriconazole impregnated spacer. She continues oral itraconazole and awaits a total knee arthroplasty. Case 3 is a 76-year-old male, who presented with a draining right heel ulcer. Radiographs revealed bony destruction consistent with Charcot arthropathy. Irrigation and debridement revealed the gelatinous destruction of the talus and calcaneus, and cultures confirmed Coccidioides infection. A polymethyl methacrylate voriconazole spacer was placed. He subsequently underwent arthrodesis and remains on lifelong fluconazole. Conclusion: Lower-extremity osteoarticular coccidioidomycosis has various debilitating presentations that frequently mimic non-infectious etiologies. Treatment warrants surgical debridement, and prolonged antifungal therapy should be considered.
- 25 July 2024
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 9 (4) , 197-205
Open AccessMusculoskeletal manifestations of lower-extremity coccidioidomycosis: a case series
Background: Coccidioidomycosis is a fungal infection endemic to the southwestern United States. Musculoskeletal manifestations are uncommon and seen in disseminated disease. While the involvement of the axial skeleton has been well described, the literature is limited on diseases involving the lower extremity. Methods: We identified three patients, at two regional academic medical centers in southern Arizona, who demonstrated different manifestations of osteoarticular coccidioidomycosis involving the lower extremity. Results: Case 1 is a 41-year-old male, with a history of HIV/AIDS and vertebral coccidioidomycosis, who presented with abscesses in the left hemipelvis and left proximal femoral osteomyelitis. He was treated with staged surgical debridement, including the use of amphotericin B impregnated beads. He remains on indefinite oral posaconazole suppression. Case 2 is a 46-year-old female, who presented with suspected right knee osteoarthritis. An MRI revealed septic arthritis and osteomyelitis. Necrotic bone was debrided, and synovial fluid cultures were positive for Coccidioides. She underwent a resection of the native knee joint with the insertion of an amphotericin B and voriconazole impregnated spacer. She continues oral itraconazole and awaits a total knee arthroplasty. Case 3 is a 76-year-old male, who presented with a draining right heel ulcer. Radiographs revealed bony destruction consistent with Charcot arthropathy. Irrigation and debridement revealed the gelatinous destruction of the talus and calcaneus, and cultures confirmed Coccidioides infection. A polymethyl methacrylate voriconazole spacer was placed. He subsequently underwent arthrodesis and remains on lifelong fluconazole. Conclusion: Lower-extremity osteoarticular coccidioidomycosis has various debilitating presentations that frequently mimic non-infectious etiologies. Treatment warrants surgical debridement, and prolonged antifungal therapy should be considered.
- 1 September 2022
- Published by American Psychological Association (APA) in Families, Systems, & Health
- Vol. 40 (3) , 383-396
Patient screening for integrated behavioral health in adult primary care: A rapid review of effective procedures.
Purpose: Although many primary care clinics screen for behavioral health (BH) conditions using validated tools, it is not clear whether adult BH screening leads to better patient outcomes. Our objective was to determine the evidence base by reviewing effectiveness research for multiple strategies of BH screening in adult primary care identified in the Practice Integration Profile. Method: We conducted five rapid reviews of effectiveness research supporting BH screening strategies cited in the Practice Integration Profile. Each rapid review was conducted using an adapted REAL (Rapid Evidence Assessment of the Literature) methodology and a standardized search tailored for each screening strategy to identify evidence related to BH screening in primary care. Results: The database search yielded 931 references. Following eligibility review and extraction, we evaluated data from 20 references examining five screening strategies. Results demonstrated limited support for all five strategies and high risk of bias within most studies. Outcomes associated with various BH screening strategies were rarely the focus of study. Conclusions: There is an absence of robust, well-structured evidence supporting many of the BH screening strategies advocated for in primary care. Stakeholders may wish to understand how to ensure value when developing a robust screening program that will improve patient health outcomes. Future research should advance the science of BH screen selection, timing, and implementation by answering new questions about screening strategies. Public Significance Statement Primary care clinicians play an important role in screening patients for unmet health needs, including behavioral health concerns. Given the broad array of potential conditions that can be identified in primary care, the ability to focus on screening strategies with the greatest potential to improve patient-centered outcomes is a meaningful advance in care. The results of our rapid reviews suggest that although screening strategies were found to be important components in some studies, additional research is needed to identify evidence-based screening strategies.
- 1 September 2022
- Published by American Psychological Association (APA) in Families, Systems, & Health
- Vol. 40 (3) , 383-396
Patient screening for integrated behavioral health in adult primary care: A rapid review of effective procedures.
Purpose: Although many primary care clinics screen for behavioral health (BH) conditions using validated tools, it is not clear whether adult BH screening leads to better patient outcomes. Our objective was to determine the evidence base by reviewing effectiveness research for multiple strategies of BH screening in adult primary care identified in the Practice Integration Profile. Method: We conducted five rapid reviews of effectiveness research supporting BH screening strategies cited in the Practice Integration Profile. Each rapid review was conducted using an adapted REAL (Rapid Evidence Assessment of the Literature) methodology and a standardized search tailored for each screening strategy to identify evidence related to BH screening in primary care. Results: The database search yielded 931 references. Following eligibility review and extraction, we evaluated data from 20 references examining five screening strategies. Results demonstrated limited support for all five strategies and high risk of bias within most studies. Outcomes associated with various BH screening strategies were rarely the focus of study. Conclusions: There is an absence of robust, well-structured evidence supporting many of the BH screening strategies advocated for in primary care. Stakeholders may wish to understand how to ensure value when developing a robust screening program that will improve patient health outcomes. Future research should advance the science of BH screen selection, timing, and implementation by answering new questions about screening strategies. Public Significance Statement Primary care clinicians play an important role in screening patients for unmet health needs, including behavioral health concerns. Given the broad array of potential conditions that can be identified in primary care, the ability to focus on screening strategies with the greatest potential to improve patient-centered outcomes is a meaningful advance in care. The results of our rapid reviews suggest that although screening strategies were found to be important components in some studies, additional research is needed to identify evidence-based screening strategies.
- Open Access
- 17 August 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (3) , 3488-3498
Time to treatment initiation and its impact on real‐world survival in metastatic colorectal cancer and pancreatic cancer
Background: Given the dearth of data regarding the time to treatment initiation (TTI) in the palliative setting, and its impact on survival outcomes, we sought to determine TTI in a real‐world cohort of metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer (mPC) patients and evaluate the impact of TTI on real‐world survival outcomes.Methods: We collected survival and treatment data for mCRC and mPC from the Flatiron Health electronic health records (EHR) derived database. We divided TTI into 3 categories: < 2 weeks, 2–< 4 weeks, and 4–8 weeks, from diagnosis to first‐line therapy. Outcome measures were median TTI, real‐world overall survival (RW‐OS) based on TTI categories by Kaplan–Meier method, and impact of TTI on survival using cox proportional hazard models.Results: Among 7108 and 3231 patients with mCRC and mPC treated within 8 weeks of diagnosis, the median TTI were 28 days and 20 days. Median RW‐OS for mCRC was 24 months; 26.9 months versus 22.6 and 18.05 months in the 4–8‐week, 2–< 4 week (control) and < 2‐week groups, respectively (p < 0.0001). For mPC, median RW‐OS was 8 months, without significant difference in RW‐OS among the groups (p = 0.05). The 4–8‐week group was associated with lower hazard of death (HR 0.782, 95% CI 0.73–0.84, p < 0.0001) and the < 2‐week group was associated with a higher hazard of death (HR 1.26, 95% CI 1.15–1.38, p < 0.0001) in mCRC. The 4–8‐week group was associated with lower hazard of death for mPC (HR 0.88, 95% CI 0.8–0.97, p = 0.0094).Conclusion: In a real‐world cohort of patients treated within 8 weeks of diagnosis, and with the limitations of a retrospective study, later TTI did not have a negative impact on survival outcomes in mCRC and mPC.
- 17 August 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (3) , 3488-3498
Open AccessTime to treatment initiation and its impact on real‐world survival in metastatic colorectal cancer and pancreatic cancer
Background: Given the dearth of data regarding the time to treatment initiation (TTI) in the palliative setting, and its impact on survival outcomes, we sought to determine TTI in a real‐world cohort of metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer (mPC) patients and evaluate the impact of TTI on real‐world survival outcomes.Methods: We collected survival and treatment data for mCRC and mPC from the Flatiron Health electronic health records (EHR) derived database. We divided TTI into 3 categories: < 2 weeks, 2–< 4 weeks, and 4–8 weeks, from diagnosis to first‐line therapy. Outcome measures were median TTI, real‐world overall survival (RW‐OS) based on TTI categories by Kaplan–Meier method, and impact of TTI on survival using cox proportional hazard models.Results: Among 7108 and 3231 patients with mCRC and mPC treated within 8 weeks of diagnosis, the median TTI were 28 days and 20 days. Median RW‐OS for mCRC was 24 months; 26.9 months versus 22.6 and 18.05 months in the 4–8‐week, 2–< 4 week (control) and < 2‐week groups, respectively (p < 0.0001). For mPC, median RW‐OS was 8 months, without significant difference in RW‐OS among the groups (p = 0.05). The 4–8‐week group was associated with lower hazard of death (HR 0.782, 95% CI 0.73–0.84, p < 0.0001) and the < 2‐week group was associated with a higher hazard of death (HR 1.26, 95% CI 1.15–1.38, p < 0.0001) in mCRC. The 4–8‐week group was associated with lower hazard of death for mPC (HR 0.88, 95% CI 0.8–0.97, p = 0.0094).Conclusion: In a real‐world cohort of patients treated within 8 weeks of diagnosis, and with the limitations of a retrospective study, later TTI did not have a negative impact on survival outcomes in mCRC and mPC.
- Open Access
- 14 June 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 32, 100588
Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients
- 14 June 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 32, 100588
Open AccessUnderstanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients
- 1 August 2020
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 59 (2) , 149-156
Impact of Medicaid Expansion on Healthcare Access Among Individuals Living With Chronic Diseases
- 1 August 2020
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 59 (2) , 149-156
Impact of Medicaid Expansion on Healthcare Access Among Individuals Living With Chronic Diseases